Estuary debuts with $103M to develop kidney disease gene therapies

Positive

AI Analysis

Summary

Estuary Biotherapeutics emerged from stealth with $103 million to advance two preclinical gene therapy candidates for the most common type of inherited kidney disease.

Outcome Details

Estuary Biotherapeutics launched with $103 million in funding to advance two preclinical gene therapy candidates

Importance:5/10

Sentiment:

0.60

gene therapykidney diseasepreclinicalfinancinglaunchinherited disease

Read the original article

Published by Endpoints News on October 16, 2026 10:30 AM

Read Original